MRI Perfusion in Adnexal Masses (MRI-CAM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02694406|
Recruitment Status : Completed
First Posted : February 29, 2016
Last Update Posted : June 27, 2018
As ovarian cancer is characterized by an anarchic neovascularization resulting in a wide number of immature microvessels. These vessels are characterized by a lack of coverage by pericytes and the higher expression of one of the receptors of Vascular Endothelial Growth Factor on both endothelial and epithelial cells of ovarian cystadenocarcinomas. These physio pathogenic characteristics have been demonstrated to be in line with variations of MR perfusion parameters.
Unlike many lesions that occur in other parts of the body, biopsy should not be performed in adnexal masses that demonstrate no evidence of peritoneal disease because it may cause spillage of cystic contents, potentially leading to iatrogenic up-staging of what may have been a malignant tumor that was limited.
|Condition or disease||Intervention/treatment|
|Complex Adnexal Masses||Device: MRI perfusion|
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Official Title:||Added Value of MRI Perfusion in Evaluation of Complex Adnexal Masses|
|Actual Study Start Date :||July 2015|
|Actual Primary Completion Date :||November 1, 2017|
|Actual Study Completion Date :||December 1, 2017|
- Device: MRI perfusion
contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
- detect the number of malignant adnexal masses [ Time Frame: 2 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02694406
|Assiut, Cairo, Egypt, 002|